Cross-protective immunity against leptospirosis elicited by a live, attenuated lipopolysaccharide mutant
- PMID: 21220775
- PMCID: PMC3071135
- DOI: 10.1093/infdis/jiq127
Cross-protective immunity against leptospirosis elicited by a live, attenuated lipopolysaccharide mutant
Abstract
Background: Leptospira species cause leptospirosis, a zoonotic disease found worldwide. Current vaccines against leptospirosis provide protection only against closely related serovars.
Methods: We evaluated an attenuated transposon mutant of Leptospira interrogans serovar Manilae (M1352, defective in lipopolysaccharide biosynthesis) as a live vaccine against leptospirosis. Hamsters received a single dose of vaccine and were challenged with the homologous serovar (Manilae) and a serologically unrelated heterologous serovar (Pomona). Comparisons were made with killed vaccines. Potential cross-protective antigens against leptospirosis were investigated.
Results: Live M1352 vaccine induced superior protection in hamsters against homologous challenge. The live vaccine also stimulated cross-protection against heterologous challenge, with 100% survival (live M1352) versus 40% survival (killed vaccine). Hamsters receiving either vaccine responded to the dominant membrane proteins LipL32 and LipL41. Hamsters receiving the live vaccine additionally recognized LA3961/OmpL36 (unknown function), Loa22 (OmpA family protein, recognized virulence factor), LA2372 (general secretory protein G), and LA1939 (hypothetical protein). Manilae LigA was recognized by M1352 vaccinates, whereas LipL36 was detected in Pomona.
Conclusion: This study demonstrated that a live, attenuated vaccine can stimulate cross-protective immunity to L. interrogans and has identified antigens that potentially confer cross-protection against leptospirosis.
Figures
Similar articles
-
Revisiting the Development of Vaccines Against Pathogenic Leptospira: Innovative Approaches, Present Challenges, and Future Perspectives.Front Immunol. 2022 Jan 3;12:760291. doi: 10.3389/fimmu.2021.760291. eCollection 2021. Front Immunol. 2022. PMID: 35046936 Free PMC article. Review.
-
Identification of in vivo expressed proteins in live attenuated lipopolysaccharide mutant that mediates heterologous protection against Leptospira spp.Vet Microbiol. 2021 Nov;262:109220. doi: 10.1016/j.vetmic.2021.109220. Epub 2021 Aug 30. Vet Microbiol. 2021. PMID: 34509026
-
Heterologous protection elicited by a live, attenuated, Leptospira vaccine.Vet Microbiol. 2018 Sep;223:47-50. doi: 10.1016/j.vetmic.2018.07.018. Epub 2018 Jul 21. Vet Microbiol. 2018. PMID: 30173751
-
A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus.Elife. 2021 Jan 26;10:e64166. doi: 10.7554/eLife.64166. Elife. 2021. PMID: 33496263 Free PMC article.
-
Expansion of the in vitro assay for Leptospira potency testing to other serovars: case study with Leptospira Hardjo.Biologicals. 2013 Sep;41(5):323-4. doi: 10.1016/j.biologicals.2013.06.003. Epub 2013 Jul 6. Biologicals. 2013. PMID: 23838569 Review.
Cited by
-
Leptospira Lipid A Is a Potent Adjuvant That Induces Sterilizing Immunity against Leptospirosis.Vaccines (Basel). 2023 Dec 6;11(12):1824. doi: 10.3390/vaccines11121824. Vaccines (Basel). 2023. PMID: 38140228 Free PMC article.
-
Lipid A structural diversity among members of the genus Leptospira.Front Microbiol. 2023 May 25;14:1181034. doi: 10.3389/fmicb.2023.1181034. eCollection 2023. Front Microbiol. 2023. PMID: 37303810 Free PMC article.
-
Challenges for the development of a universal vaccine against leptospirosis revealed by the evaluation of 22 vaccine candidates.Front Cell Infect Microbiol. 2022 Oct 7;12:940966. doi: 10.3389/fcimb.2022.940966. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36275031 Free PMC article.
-
Pathogenic Leptospires Limit Dendritic Cell Activation Through Avoidance of TLR4 and TRIF Signaling.Front Immunol. 2022 Jun 22;13:911778. doi: 10.3389/fimmu.2022.911778. eCollection 2022. Front Immunol. 2022. PMID: 35812397 Free PMC article.
-
Revisiting the Development of Vaccines Against Pathogenic Leptospira: Innovative Approaches, Present Challenges, and Future Perspectives.Front Immunol. 2022 Jan 3;12:760291. doi: 10.3389/fimmu.2021.760291. eCollection 2021. Front Immunol. 2022. PMID: 35046936 Free PMC article. Review.
References
-
- Adler B, de la Pena Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140:287–96. - PubMed
-
- McBride AJ, Athanazio DA, Reis MG, Ko AI. Leptospirosis. Curr Opin Infect Dis. 2005;18:376–86. - PubMed
-
- Bolin CA, Alt DP. Use of a monovalent leptospiral vaccine to prevent renal colonization and urinary shedding in cattle exposed to Leptospira borgpetersenii serovar Hardjo. Am J Vet Res. 2001;62:995–1000. - PubMed
-
- Feigin RD, Lobes LA, Jr, Anderson D, Pickering L. Human leptospirosis from immunized dogs. Ann Intern Med. 1973;79:777–85. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
